US9802931B2ActiveUtilityA1

Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors

69
Assignee: NOVARTIS AGPriority: Jul 15, 2011Filed: Jan 15, 2016Granted: Oct 31, 2017
Est. expiryJul 15, 2031(~5 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 9/06A61P 9/10A61P 9/12A61P 25/18A61P 25/30A61P 25/22A61P 25/28A61P 25/08A61P 27/02A61P 25/24A61P 25/16A61P 29/00A61P 25/06A61P 15/10A61P 19/02A61P 25/00C07D 453/02A61K 31/439C07C 57/15C07C 57/145A61K 2300/00C07D 487/08C07C 51/412A61K 9/2054C07D 209/00C07C 55/08A61K 31/194C07D 213/61C07B 2200/13C07B 2200/07C07C 55/10
69
PatentIndex Score
1
Cited by
46
References
8
Claims

Abstract

The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. A process for the production of a compound of formula I 
       
         
           
           
               
               
           
         
       
       or a salt thereof, the process comprising:
 reacting a compound of formula II 
 
       
         
           
           
               
               
           
         
       
       or a salt thereof, with a compound of formula V 
       
         
           
           
               
               
           
         
       
       or a salt thereof, at elevated temperature in the presence of a base and an inert dipolar aprotic solvent,
 wherein the base is (M 2 )OC(R) 3 , wherein M 2  is sodium or potassium and each R independently is C 1-6 alkyl or two R together with the carbon atom they are bound to form C 4-6  cycloalkyl, or the base is a hydroxide base, 
 to form the compound of formula I; and 
 optionally converting the compound of formula Ito a salt thereof. 
 
     
     
       2. The process according to  claim 1 , wherein the base is gradually added to the reaction mixture. 
     
     
       3. The process according to  claim 1 , wherein the base is sodium tert-butanolate or potassium tert-butanolate. 
     
     
       4. The process according to  claim 1 , wherein the inert dipolar aprotic solvent is dimethylsulfoxide. 
     
     
       5. The process according to  claim 4 , wherein the reaction mixture further comprises toluene. 
     
     
       6. The process according to  claim 1 , further comprising producing the compound of formula II or the salt thereof 
       
         
           
           
               
               
           
         
       
       according to a process comprising:
 a) reacting a compound of formula III 
 
       
         
           
           
               
               
           
         
       
       with a compound of formula IV 
       
         
           
           
               
               
           
         
       
       and/or with a compound of formula IVA 
       
         
           
           
               
               
           
         
       
       wherein M 1  is alkali and n is 1, or M 1  is earth alkali and n is 2; 
       in the presence of a palladium catalyst; a base selected from a carbonate base, a phosphate base, a hydroxide base, and an alcoholate base; water and an inert solvent; 
       to form the compound of formula II; and
 b) optionally converting the compound of formula II to a salt thereof. 
 
     
     
       7. The process according to  claim 6 , wherein the reaction of the compound of formula III with the compound of formula IV and/or the compound of formula IVA is carried out at a pH from 10.5 to 13. 
     
     
       8. The process according to  claim 6 ,
 wherein the inert solvent is a partly water soluble solvent; 
 wherein cysteine is added to the biphasic reaction mixture after formation of the compound of formula II; the phases are separated; and the compound of formula II is isolated from the non-aqueous phase.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.